Low-dose triple antihypertensive combination therapy in patients with hypertension: A randomized, double-blind, phase ii study

Soon Jun Hong, Ki Chul Sung, Sang Wook Lim, Seokyeon Kim, Weon Kim, Jinho Shin, Sungha Park, Hae Young Kim, Moo Yong Rhee

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: We evaluated the dose-responsiveness, efficacy, and safety of low-dose triple antihypertensive combination therapies in patients with mild-to-moderate hypertension. Patients and Methods: After a 1 to 2-week placebo run-in period, 248 patients were randomized to the half-dose triple combination (amlodipine 2.5 mg + losartan 25 mg + chlorthalidone 6.25 mg), third-dose triple combination (amlodipine 1.67 mg + losartan 16.67 mg + chlorthalidone 4.17 mg), quarter-dose triple combination (amlodipine 1.25 mg + losartan 12.5 mg + chlorthalidone 3.13mg), amlodipine 10mg, amlodipine 5mg, losartan 100mg, and placebo groups for 8 weeks. The primary outcome was the mean change in systolic blood pressure (SBP) from baseline to week 8. Results: The placebo-corrected SBP reductions of the half-dose, third-dose, quarter-dose combination, amlodipine 10 mg, amlodipine 5 mg and losartan 100 mg treatments were −17.2, −19.5, −14.9, −18.5, −11.3 and −9.9 mmHg, respectively. The BP control and response rates were significantly higher in the half-dose, third-dose, and quarter-dose combination groups than in the placebo group (all p < 0.01). Despite no intergroup differences in study drug-related adverse events, ankle circumference increased significantly in the amlo-dipine group compared to those in the combination treatment groups. The quarter-dose combination, amlodipine 5 mg, and losartan 100 mg groups showed similar SBP reduction and BP response rates. The SBP reduction and BP response rate in the third-dose and half-dose combination groups were not significantly different from those in the amlodipine 10 mg group but superior to those in the losartan 100 mg group. Conclusion: Low-dose triple combination therapies could be effective as antihypertensive therapies. Trial Registration: ClinicalTrials.gov identifier NCT03897868.

Original languageEnglish
Pages (from-to)5735-5746
Number of pages12
JournalDrug Design, Development and Therapy
Volume14
DOIs
Publication statusPublished - 2020

Bibliographical note

Funding Information:
M.Y . Rhee has received lecture honoraria from Pfizer Inc., LG Life Sciences Ltd., Boehringer Ingelheim Pharma GmbH & Co. KG., Hanmi Pharm. Co. Ltd., Y uhan Co. Ltd., and Boryung Pharmaceutical Co. Ltd.; consulting fees from Hanmi Pharm. Co. Ltd. and Shin Poong Pharma. Co. Ltd.; and research grants from Boryung Pharmaceutical Co. Ltd. and Dong-A Pharmaceutical Co. Ltd. J. Shin has received lecture honoraria from Pfizer Inc., Hanmi Pharm. Co. Ltd., Y uhan Co. Ltd., and Boryung Pharmaceutical Co. Ltd.; consulting fees from Hanmi Pharm. Co. Ltd.; and research grants from Sanofi Pharm. and Hanmi Pharm. Co. Ltd. S. Park has received lecture honoraria from Pfizer Inc., Hanmi Pharm. Co. Ltd, Boryung Pharmaceutical Co. Ltd, Daewoong Pharmaceutical Co. Ltd, Sankyo Pharmaceutical Co. Ltd, T akeda Pharmaceutical Co. Ltd, Dong-A Pharmaceutical Co. Ltd. and Servier Pharmaceutical Co. Ltd., and a research grant from Sankyo Pharmaceutical Co. Ltd. The other authors have indicated that they have no conflicts of interest with regard to the content of this article.

Funding Information:
was provided by Hanmi Pharmaceutical Co. Ltd., Seoul, Republic of Korea.

Publisher Copyright:
© 2020 Hong et al.

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Low-dose triple antihypertensive combination therapy in patients with hypertension: A randomized, double-blind, phase ii study'. Together they form a unique fingerprint.

Cite this